Biological
NBP607-QIV
NBP607-QIV is a biological therapy with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
20%(1 trials)
Phase Distribution
Ph phase_1
1
20%
Ph phase_3
4
80%
Phase Distribution
1
Early Stage
0
Mid Stage
4
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 3Large-scale testing
4(80.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (20.0%)
Phase 34 (80.0%)
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_3
Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months
NCT03704740
completedphase_3
Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects
NCT02467842
completedphase_1
Safety, Tolerability and Immunogenicity of NBP607QIV in Healthy Adult Volunteers
NCT03826719
completedphase_3
Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months
NCT03020628
completedphase_3
Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents
NCT02621164
Clinical Trials (5)
Showing 5 of 5 trials
NCT03704740Phase 3
Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months
NCT02467842Phase 3
Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects
NCT03826719Phase 1
Safety, Tolerability and Immunogenicity of NBP607QIV in Healthy Adult Volunteers
NCT03020628Phase 3
Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months
NCT02621164Phase 3
Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents
All 5 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 5